Quorum Innovations is a biopharmaceutical company dedicated to the discovery and development of therapeutics that leverage the human microbiome, which is increasingly recognized as a critical component of human health. The company employs its proprietary MiNE™ discovery platform to identify and develop Probiomic™ therapeutics, which aim to restore balance in the microbiome by shifting dysbiotic states to eubiosis. This approach is particularly focused on addressing chronic inflammatory conditions and diseases related to tissue barrier deficiencies, such as atopic dermatitis, allergic rhinitis, and dry eye syndrome. Quorum's innovative strategies are rooted in translational medicine, ensuring that their research is closely aligned with clinical needs.

One of Quorum Innovations' notable products is BioEsse, a probiotic essence designed for skin health, which exemplifies their commitment to developing microbiome-centered treatments. The company has also made significant advancements in modulating the skin microbiota to enhance immune responses and improve skin barrier function. Utilizing strains like Lactobacillus fermentum, Quorum's therapeutics promote the growth of beneficial bacteria while inhibiting harmful pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA). Through its focus on the human microbiome, Quorum Innovations aims to redefine therapeutic approaches and establish itself as a leader in the emerging field of microbiome therapeutics.

United States

Biotechnology and drug discovery developing microbiome therapeutics and direct to consumer products.  Early stage company with a completion of a licensing agreement, a consumer product BioEsse, (A Probiotic Essensce for the Skin), in production, and medical indication for NDA and integrated development plan in progress.

Quorum Innovations

Company Details